
Dosing
In metastatic EGFRm NSCLC
Once-daily TAGRISSO can be taken any time of day,* with or without food1
One 80-mg tablet once a day
Pill image is not actual size.
*At the same time each day.
For patients who have difficulty swallowing pills1
EGFRm, epidermal growth factor receptor mutant; NG, nasogastric; NSCLC, non-small cell lung cancer.
Reference: 1. TAGRISSO [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.
TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test
TAGRISSO is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test
TAGRISSO is indicated for the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy
For additional information, please see the complete Prescribing Information, including Patient Information.
You may report side effects related to AstraZeneca products by clicking here.